Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatm⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$35.77
Price+2.23%
$0.78
$3.285b
Mid
-
Premium
Premium
-19.6%
EBITDA Margin-9.8%
Net Profit Margin-11.2%
Free Cash Flow Margin$797.735m
+59.9%
1y CAGR+78.0%
3y CAGR+63.1%
5y CAGR-$325.774m
+45.0%
1y CAGR+4.4%
3y CAGR-3.5%
5y CAGR-$3.54
+46.6%
1y CAGR+13.1%
3y CAGR+8.2%
5y CAGR$1.036b
$1.690b
Assets$647.499m
Liabilities$387.919m
Debt23.0%
-1x
Debt to EBITDA-$290.365m
+58.0%
1y CAGR-20.0%
3y CAGR-12.5%
5y CAGR